1. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems 2013
2. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole 2013
3. FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects 2013
4. Liver injury associated with ketoconazole: Review of the published evidence;Greenblatt;J Clin Pharmacol,2014
5. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database;Raschi;World Journal of Hepatology,2014